BCDIN3D Inhibitors
Chemical inhibitors of BCDIN3D function through multiple mechanisms, primarily by affecting the kinase-mediated phosphorylation state that is critical for its activity. Bisindolylmaleimide I, a protein kinase C (PKC) inhibitor, can disrupt the PKC signaling that is potentially required for the optimal functioning of BCDIN3D. Similarly, H-89 targets protein kinase A (PKA), leading to reduced phosphorylation events that BCDIN3D may depend on for its activity. Staurosporine, a broad-spectrum kinase inhibitor, can interfere with the phosphorylation of BCDIN3D by inhibiting a wide range of kinases that would otherwise contribute to its activation state. SP600125 and SB203580, which inhibit JNK and p38 MAP kinase respectively, can decrease the phosphorylation-mediated regulation of BCDIN3D, assuming the involvement of these kinases in its modulation. PP2, an Src family kinase inhibitor, and LFM-A13, a Bruton's tyrosine kinase (BTK) inhibitor, reduce the activity of kinases that may regulate BCDIN3D through phosphorylation.
Further affecting the phosphorylation landscape that governs BCDIN3D activity are PI3K inhibitors LY294002 and Wortmannin. Both chemicals can suppress the PI3K/Akt pathway, which is known to regulate the activity of various proteins, including methyltransferases like BCDIN3D. Rapamycin, as an mTOR inhibitor, can undermine the functional state of BCDIN3D by inhibiting downstream protein synthesis processes that might be crucial for its activity. U0126 and PD98059, both MEK inhibitors, prevent the activation of ERK kinase, which could be necessary for the phosphorylation-dependent activation of BCDIN3D. The inhibition of these kinases leads to a decrease in the functional capacity of BCDIN3D due to reduced phosphorylation and subsequent activation of the protein. Together, these chemical inhibitors constitute a network of interventions that target the signaling pathways and kinase activities essential for the functional expression of BCDIN3D.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a protein kinase C (PKC) inhibitor. BCDIN3D, as a methyltransferase, may rely on PKC-mediated signaling for optimal activity. Inhibition of PKC can reduce phosphorylation events that might be necessary for BCDIN3D function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K/Akt signaling can regulate various proteins, including methyltransferases. By inhibiting this pathway, LY294002 can reduce the phosphorylation state affecting BCDIN3D's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which similarly to LY294002, can decrease the activation state of pathways that regulate methyltransferase activity, ultimately leading to a reduction in BCDIN3D function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway can influence protein synthesis and function; by inhibiting mTOR, rapamycin can decrease the functional state of proteins like BCDIN3D. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of many protein kinases. By broadly inhibiting kinases, it can reduce the phosphorylation and activation states of various proteins, potentially including BCDIN3D. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a c-Jun N-terminal kinase (JNK) inhibitor. JNK can regulate protein function by phosphorylation; inhibiting JNK can lead to a decrease in BCDIN3D activity if it is regulated by JNK-mediated phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which can control protein function via phosphorylation. Inhibiting p38 MAP kinase can lead to reduced phosphorylation and consequent functional inhibition of BCDIN3D. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can regulate protein function through phosphorylation; inhibiting these kinases can reduce phosphorylation-dependent activity of BCDIN3D. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor similar to U0126. It can decrease ERK-mediated phosphorylation, which could be necessary for the activation or optimal function of BCDIN3D. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is implicated in the regulation of various signaling pathways, and by inhibiting BTK, LFM-A13 can diminish phosphorylation-dependent regulation of BCDIN3D. | ||||||